#None #Class Action #Robbins LLP #Switzerland #MoonLake Immuno

Recent Class Action Alert Against MoonLake Immunotherapeutics

In a significant development, stockholders of MoonLake Immunotherapeutics (MLTX) are being urged to act quickly following the announcement of a class action lawsuit aimed at the company. This legal pursuit involves investors who acquired shares during a specified period, highlighted by claims that the company provided misleading information regarding the effectiveness of its drug candidate.

Overview of MoonLake Immunotherapeutics

MoonLake Immunotherapeutics operates out of Switzerland and is a clinical-stage biotechnology firm specializing in treatments targeting inflammatory diseases. The company's primary focus is the cytokine interleukin-17 (IL-17), which is relevant in conditions affecting both dermatology and rheumatology.

The Allegations

The class action lawsuit centers on several critical allegations against MoonLake, including misleading claims about the efficacy of its drug SLK. The key points of contention include:
1. Molecular Misrepresentation: The complaint asserts that important distinctions between the company's Nanobodies and conventional monoclonal antibodies were not adequately communicated. Specifically, both SLK and BIMZELX, a drug already approved by the FDA, target similar inflammatory cytokines.
2. Clinical Benefit Misleading: There are claims that the unique structure of SLK's Nanobody does not offer any significant clinical advantages over BIMZELX's monoclonal structure.
3. Questionable Efficacy: Concerns have also been raised about the actual clinical efficacy of SLK, especially following its failure to demonstrate competitive performance in recent trials.

On September 28, 2025, MoonLake's announcement regarding the week-16 results from its Phase 3 VELA program showed that SLK did not perform as expected. The immediate aftermath saw the company’s stock price plunge dramatically, losing close to 90% of its value within a single day.

Legal Steps for Affected Shareholders

The implications for shareholders could be substantial. If you purchased shares of MoonLake between March 10, 2024, and September 29, 2025, you may qualify to participate in the class action. Affected individuals are encouraged to consider serving as lead plaintiffs, which requires submission of necessary paperwork by December 15, 2025. Moreover, it’s important to note that participating in the case is not a prerequisite for recovery.

For more information regarding this class action, interested parties can reach out to Robbins LLP directly. The firm's attorney Aaron Dumas, Jr. is handling inquiries related to this case, and they can be contacted via phone at (800) 350-6003 or through their official website.

About Robbins LLP

Robbins LLP is well-regarded in the realm of shareholder rights litigation. Since its inception in 2002, the firm has focused on ensuring that shareholders reclaim losses sustained due to corporate malfeasance. They specialize in enhancing corporate governance and holding negligent executives accountable for their actions.

Conclusion

As this legal situation continues to unfold, it is crucial for MoonLake Immunotherapeutics stockholders to remain informed about potential developments in the class action. By staying engaged and proactive, investors can ensure their voices are heard in this important matter that could affect the financial landscape surrounding MoonLake Immunotherapeutics.

For regular updates and information about the class action and recovery options, interested individuals can sign up for alerts through Stock Watch, offered by Robbins LLP.